6 results
The primary objective of this study is to compare the overall survival (OS) of ramucirumab DP administered in combination with docetaxel versus docetaxel with placebo as therapy for patients with Stage IV non-small cell lung cancer (NSCLC) who have…
Primary objective:• To evaluate biodistribution of 89Zr-atezolizumab in patients with high risk DLBCL at diagnosis.Secondary objective:• To assess the heterogeneity of 89Zr-atezolizumab tumor uptake in high-risk DLBCL before R-CHOP.• To correlate…
In this study, we want to find out whether the new drug capmatinib is more effective (i.e. better inhibits the growth of cancer cells) than the widely used chemotherapy docetaxel. In addition, it will be assessed whether treatment with capmatinib is…
The study will look at patients with Squamous Cell Head and Neck Cancer (SCCHN) whose tumours express a certain type of protein called PD-L1. The research aims to compare a new drug called nivolumab against Investigator's choice of chemotherapy…
To compare the overall survival (OS) of sacituzumab govitecan (SG) versus docetaxel.
This study compares the efficacy of tafasitamab + lenalidomide + rituximab to the efficacy of placebo + lenalidomide + rituximab in terms of progression-free survival (PFS) in participants with R/R follicular lymphoma. In addition, the efficacy of…